sorafenib has been researched along with topotecan in 8 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (topotecan) | Trials (topotecan) | Recent Studies (post-2010) (topotecan) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 2,392 | 626 | 792 |
Protein | Taxonomy | sorafenib (IC50) | topotecan (IC50) |
---|---|---|---|
Cytochrome P450 3A4 | Homo sapiens (human) | 1.5211 | |
DNA topoisomerase 1 | Homo sapiens (human) | 0.8525 | |
DNA topoisomerase 2-alpha | Homo sapiens (human) | 0.605 | |
DNA topoisomerase 2-beta | Homo sapiens (human) | 0.605 | |
Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.06 | |
Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 8.6 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.3 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.17 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 8 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Amen, Y; El-Sayed, MA; Kitamura, M; Okauchi, T; Othman, DIA; Selim, KB; Shimizu, K; Tantawy, AS | 1 |
Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E | 1 |
Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C | 1 |
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
Braicu, EI; Chekerov, R; De Gregorio, N; du Bois, A; El-Balat, A; Fridrich, C; Harter, P; Hilpert, F; Krabisch, P; Lorenz, R; Lueck, HJ; Mahner, S; Markmann, S; Oskay-Oezcelik, G; Potenberg, J; Richter, R; Schmidt, M; Sehouli, J | 1 |
Corrado, G; Ferrandina, G | 1 |
1 review(s) available for sorafenib and topotecan
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for sorafenib and topotecan
Article | Year |
---|---|
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan | 2011 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Germany; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Sorafenib; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2018 |
4 other study(ies) available for sorafenib and topotecan
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Design, Synthesis and Anticancer Evaluation of New Substituted Thiophene-Quinoline Derivatives.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Caspase 9; Cell Proliferation; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Molecular Structure; Quinolines; Structure-Activity Relationship; Thiophenes | 2019 |
Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Cells, Cultured; Dogs; Humans; Indoles; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Topoisomerase I Inhibitors; Topotecan | 2011 |
Treatment of platinum refractory or resistant ovarian cancer.
Topics: Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sorafenib; Topotecan | 2018 |